BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17201059)

  • 1. [The innate antiretroviral defense of human cells, based on the DNA editing].
    Pupecka M; Pacak A
    Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good to CU.
    Gu Y; Sundquist WI
    Nature; 2003 Jul; 424(6944):21-2. PubMed ID: 12840737
    [No Abstract]   [Full Text] [Related]  

  • 4. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
    Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
    Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
    J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    Sawyer SL; Emerman M; Malik HS
    PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death by deamination: a novel host restriction system for HIV-1.
    Goff SP
    Cell; 2003 Aug; 114(3):281-3. PubMed ID: 12914693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.
    Argyris EG; Pomerantz RJ
    Trends Microbiol; 2004 Apr; 12(4):145-8. PubMed ID: 15116720
    [No Abstract]   [Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
    Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
    J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virology. Weapons of mutational destruction.
    KewalRamani VN; Coffin JM
    Science; 2003 Aug; 301(5635):923-5. PubMed ID: 12920286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.